Literature DB >> 17196049

Remission in first-episode psychosis: predictor variables and symptom improvement patterns.

Robin Emsley1, Piet P Oosthuizen, Martin Kidd, Liezl Koen, Dana J H Niehaus, H Jadri Turner.   

Abstract

BACKGROUND: Previous attempts to identify clinically useful predictors of treatment outcome in schizophrenia have been hampered by methodological inconsistencies, including a lack of standardized outcome measures. Recently proposed operationally defined criteria for remission provide an opportunity to readdress this topic.
METHOD: We applied the remission criteria to a sample of 57 subjects with first-episode psychosis (DSM-IV schizophrenia, schizoaffective disorder, or schizophreniform disorder), treated according to a fixed protocol in a prospective study. Subjects were recruited between April 1999 and January 2000 and were followed for 2 years. Various demographic, baseline clinical, and early-response variables were subjected to discriminant analysis for their ability to predict remission or nonremission. We also assessed the symptom improvement patterns over time and compared endpoint psychopathology in the remitters and nonremitters.
RESULTS: A model incorporating neurologic soft signs, 6-week treatment response, duration of untreated psychosis, marital status, and Positive and Negative Syndrome Scale excited factor baseline score was able to correctly predict 89% of the remitters and 86% of the nonremitters. Symptom reduction at 6 weeks, including core psychotic symptoms, was significant in both groups (remitters, p < .0001; nonremitters, p < .0001), although reduction was substantially greater in the remission group (p = .004). Thereafter, the remission group continued to improve (p < .01), while the nonremitting group failed to do so (p = .55). Considerable overlap of endpoint symptoms was observed, and depressive symptom scores were similar in remitters and nonremitters.
CONCLUSION: A combination of demographic, baseline clinical, and acute treatment response variables may accurately predict treatment outcome. Persistent noncore psychotic symptoms in subjects meeting proposed remission criteria require further investigation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17196049     DOI: 10.4088/jcp.v67n1106

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  19 in total

1.  Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?

Authors:  Juan A Gallego; Delbert G Robinson; Serge M Sevy; Barbara Napolitano; Joanne McCormack; Martin L Lesser; John M Kane
Journal:  J Clin Psychiatry       Date:  2011-09-06       Impact factor: 4.384

2.  Evaluation of a multi-element treatment center for early psychosis in the United States.

Authors:  Sarah R Uzenoff; David L Penn; Karen A Graham; Sylvia Saade; Barbara B Smith; Diana O Perkins
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-01-26       Impact factor: 4.328

3.  Early response or nonresponse at week 2 and week 3 predict ultimate response or nonresponse in adolescents with schizophrenia treated with olanzapine: results from a 6-week randomized, placebo-controlled trial.

Authors:  Marie Stentebjerg-Olesen; Stephen J Ganocy; Robert L Findling; Kiki Chang; Melissa P DelBello; John M Kane; Mauricio Tohen; Pia Jeppesen; Christoph U Correll
Journal:  Eur Child Adolesc Psychiatry       Date:  2015-06-02       Impact factor: 4.785

4.  Therapeutic abstention in the treatment of depression in first-episode psychosis.

Authors:  Priyadharshini Sabesan; Lena Palaniyappan
Journal:  J Psychiatry Neurosci       Date:  2020-11       Impact factor: 6.186

5.  Association between financial strain, social network and five-year recovery from first episode psychosis.

Authors:  Maria Mattsson; Alain Topor; Johan Cullberg; Yvonne Forsell
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2008-07-05       Impact factor: 4.328

6.  Remission status and cortical thickness in childhood-onset schizophrenia.

Authors:  Deanna K Greenstein; Sarah Wolfe; Peter Gochman; Judith L Rapoport; Nitin Gogtay
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2008-10       Impact factor: 8.829

Review 7.  Remission in schizophrenia: validity, frequency, predictors, and patients' perspective 5 years later.

Authors:  Martin Lambert; Anne Karow; Stefan Leucht; Benno G Schimmelmann; Dieter Naber
Journal:  Dialogues Clin Neurosci       Date:  2010       Impact factor: 5.986

Review 8.  Clinical predictors of therapeutic response to antipsychotics in schizophrenia.

Authors:  Maren Carbon; Christoph U Correll
Journal:  Dialogues Clin Neurosci       Date:  2014-12       Impact factor: 5.986

9.  Long-term healthcare costs and functional outcomes associated with lack of remission in schizophrenia: a post-hoc analysis of a prospective observational study.

Authors:  Virginia S Haynes; Baojin Zhu; Virginia L Stauffer; Bruce J Kinon; Michael D Stensland; Lei Xu; Haya Ascher-Svanum
Journal:  BMC Psychiatry       Date:  2012-12-05       Impact factor: 3.630

10.  Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER).

Authors:  Seung-Ho Jung; Jin-Sang Yoon; Yong-Min Ahn; Yong-Sik Kim; Chul-Eung Kim
Journal:  Psychiatry Investig       Date:  2013-12-16       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.